HLA
OSE Immunotherapeutics Starts Registration-Directed Tedopi Trial in Second-Line NSCLC
The firm is also evaluating a test to identify HLA-A2-positive patients eligible for the neoepitope-based cancer vaccine.
FDA Approves Adaptimmune's TCR Therapy Tecelra for Certain Synovial Sarcoma Patients
The accelerated approval marks the first time the FDA has approved an engineered autologous cell therapy for a solid tumor indication.
Replay, MD Anderson Venture Syena Bets on NK Cells to Bring TCR Therapy to Solid, Blood Cancers
Premium
After launching the first therapy, NY-ESO-1 TCR/IL-15 NK, in a multiple myeloma trial earlier this month, Syena is exploring the approach in new targets and tumor types.
Syena Starts Cell Therapy Trial in NY-ESO-1-Positive Multiple Myeloma
The Replay and MD Anderson subsidiary has treated the first multiple myeloma patient with its cord blood-derived TCR-NK cell therapy in a Phase I/II trial.
COVID-19 Protection Provided by HLA Genetic Variant, Study Suggests
Using data from bone marrow registry participants, researchers found an HLA variant linked to symptom-free SARS-CoV-2 infection and better immune cell responses.